首页> 美国卫生研究院文献>Wiley-Blackwell Online Open >Endovascular Method for Transplantation of Insulin-Producing Cells to the Pancreas Parenchyma in Swine
【2h】

Endovascular Method for Transplantation of Insulin-Producing Cells to the Pancreas Parenchyma in Swine

机译:猪胰脏实质移植胰岛素产生细胞的血管内方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Insulin-producing cells are transplanted by portal vein injection as an alternative to pancreas transplantation in both clinical and preclinical trials. Two of the main limitations of portal vein transplantation are the prompt activation of the innate immunity and concomitant loss of islets and a small but significant risk of portal vein thrombosis. Furthermore, to mimic physiological release, the insulin-producing cells should instead be located in the pancreas. The trans-vessel wall approach is an endovascular method for penetrating the vessel wall from the inside. In essence, a working channel is established to the parenchyma of organs that are difficult to access by percutaneous technique. In this experiment, we accessed the extra-vascular pancreatic parenchyma in swine by microendovascular technique and injected methylene blue, contrast fluids and insulin-producing cells without acute adverse events. Further, we evaluated the procedure itself by a 1-year angiographical follow-up, without adverse events. This study shows that the novel approach utilizing endovascular minimal invasiveness coupled to accurate trans-vessel wall placement of an injection in the pancreatic parenchyma with insulin-producing cells is possible. In clinical practice, the potential benefits compared to portal vein cell transplantation should significantly improve endocrine function of the graft and potentially reduce adverse events.This study presents one-year follow-up safety data on the microendovascular trans-vessel wall technique and shows that the technique can be used to transplant insulin-producing cells to the swine pancreas parenchyma.
机译:在临床和临床前试验中,通过门静脉注射移植产生胰岛素的细胞,以替代胰腺移植。门静脉移植的两个主要局限性是先天免疫的迅速激活和胰岛的同时丢失以及门静脉血栓形成的风险很小但很显着。此外,为了模拟生理释放,胰岛素产生细胞应改为位于胰腺中。跨血管壁方法是用于从内部穿透血管壁的血管内方法。实质上,建立了通向经皮技术难以进入的器官实质的工作通道。在本实验中,我们通过微血管内技术进入了猪的血管外胰腺实质,并注射了亚甲蓝,造影剂和胰岛素产生细胞,而没有发生急性不良事件。此外,我们通过1年的血管造影随访评估了手术本身,没有不良事件。这项研究表明,利用血管内微创技术与胰岛素生产细胞在胰腺实质中准确注射跨血管壁的新方法是可行的。在临床实践中,与门静脉细胞移植相比,其潜在益处应能显着改善移植物的内分泌功能,并可能减少不良事件。这项研究提供了微血管跨壁血管壁技术的一年随访安全性数据,并表明该技术可用于将产生胰岛素的细胞移植到猪胰腺实质中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号